2026 IMS | Updated FUMANBA-1 Analysis of IASO Bio's FUCASO Reveals That In Vivo Durable Persistence of CAR-T cells Is Associated with Sustained MRD Negativity and Delayed Disease Progression

Data ReadoutpositiveEquecabtagene AutoleucelFucasoPositive

AI Analysis

Summary

IASO Bio presented updated analysis of 102 patients from the FUMANBA-1 study showing durable CAR-T cell persistence associated with sustained MRD-negativity and delayed disease progression for Equecabtagene Autoleucel (Fucaso). The retrospective analysis demonstrated positive clinical outcomes supporting the drug candidate's profile.

Clinical Trial Data

Primary Endpoint

Met

Patients

102

Outcome Details

Updated FUMANBA-1 analysis of 102 patients demonstrates durable CAR-T cell persistence associated with sustained MRD-negativity and delayed disease progression

Importance:6/10

Sentiment:

0.70

CAR-Tclinical dataFUMANBA-1MRD negativityIMS 2026

Read the original article

Published by PR Newswire Pharma on September 25, 2026 2:54 PM

Read Original